Kyverna Therapeutics names Nadia Dac as Chief Commercial Officer to lead launch of new autoimmune therapy.

Kyverna Therapeutics has appointed Nadia Dac as Chief Commercial Officer to spearhead the commercial launch of miv-cel, a promising CAR T-cell therapy for autoimmune diseases like stiff person syndrome. Dac brings over 30 years of experience in biopharma commercial leadership, having led successful product launches in neurology and rare diseases. Her role is crucial as Kyverna prepares to transition to a commercial-stage company and expand miv-cel’s use into other neuroimmunology conditions. The company also granted her stock options as part of her employment inducement.